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A validated ovinemodel of osteoporosis achieves severe bone loss in a relatively short period. This study investigated if osteoporotic
features persist in this model after cessation of corticosteroid administration. Methods. Osteoporosis was induced in nine ewes
by chronic corticosteroid injection, ovariectomy, and low calcium diet. Six ewes were used as controls. Bone mineral density
(BMD) of the lumbar spine (LS) and body weight were assessed at regular intervals. After five months, corticosteroid treatment
was withdrawn systematically over one month. Three months later, all animals were euthanised, and the LS was collected for
histomorphometric analysis. Results. BMD in the LS of osteoporotic sheep was 25% lower than control sheep. Body weight
of osteoporotic sheep was reduced in the first month of the corticosteroid withdrawal period but returned to baseline level
thereafter. Trabecular bone volume of LS in osteoporotic sheep was 27% lower than controls and showed a heterogeneous
structure. Conclusions. Osteoporotic characteristics remain in the vertebra after ceasing corticosteroid administration providing an
opportunity to evaluate potential systemic or local treatments in vivo under realistic physiological conditions. The microstructural
arrangement of vertebral trabecular bone in sheep is similar to humans demonstrating further relevance of this model for
preclinical investigations.
1. Introduction
Osteoporosis is a generalised condition of decreased bone
mass that is characterised by a significant increase in the
likelihood of skeletal fractures [1, 2]. Of all the fractures
associated with osteoporosis, just under 50% occur in the
spine with the remainder fairly evenly distributed between
the hips, wrists, and other skeletal sites [3]. According to
the World Health Organisation, osteoporosis is a “silent
epidemic” [4] which is increasing as the population ages.
It is estimated that 10 million people in the USA and 1.9
million people in Australia already have osteoporosis, and
it is expected that these numbers will double over the next
decade [5].
Various animal models have been utilised to investigate
the osteoporotic condition in order to facilitate preclinical
testing of pharmaceutical agents and to evaluate other
treatment options. The ovariectomised rat is recognised
by the U.S. Food and Drug Administration as a suitable
animal model [6] but due to limitations, such as lack
of true lamellar bone and Haversian systems and being
relatively small, there is still a need for a complementary
large animal model to improve orthopaedic procedures by
developing new implants and fixation strategies [7]. In
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our experience, osteoporosis can be induced in sheep with
ovariectomy, low calcium diet, and weekly corticosteroid
injection for up to 6 months [8] and although this model
(as is the case with all animal models) does not specifically
mimic either postmenopausal or glucocorticoid-induced
osteoporosis in humans, it does achieve severe bone loss in a
relatively short period and displays many pathophysiological
features that are similar to the human osteoporotic state
[8–10]. Further, it oﬀers the convenience of conducting
spinal surgery and preclinical testing of devices (including
pharmaceuticals at similar doses) intended for use in humans
under highly relevant clinical conditions. It is our view that
this model would be further enhanced by terminating steroid
administration after induction of osteoporosis to remove
potential confounding interactions of the corticosteroids
with proposed interventions. Thus, the aim of this study
was to characterise the morphological features of vertebral
bone in this model after withdrawal of the corticosteroid
injection regimen [11, 12]. The hypothesis tested was that
vertebral BMD and bone architecture, as indicators of bone
quality [13–15] in osteoporotic sheep, remain unchanged
after cessation of corticosteroid administration.
2. Materials and Methods
2.1. Animal Preparation. With Institutional Animal Ethics
Committee approval nine 3-year-old Merino ewes, (mean
weight 66.3 ± 8 kg) were bilaterally ovariectomised under
general anaesthesia. The animals were housed in barren
pens and fed a low calcium diet with weekly intramuscular
injections of corticosteroid [8]. These sheep comprised the
osteoporotic group. Bone mineral density (BMD) of the
lumbar spine (L2 to L5) was assessed monthly by DXA
and when it was reduced by at least 25% from baseline,
the corticosteroid was withdrawn to permit resumption of
natural cortisol production. The animals were maintained
on a low calcium diet. Since rapid withdrawal of corti-
costeroid can result in acute adrenal insuﬃciency [16], it
was systematically reduced by 50% each week until the
end of the fourth week when it was stopped altogether.
Six age-matched control sheep (mean weight 65.7 ± 7 kg)
underwent sham abdominal surgery and were fed a normal
diet. All animals were observed for their appetite and general
wellbeing during the experiment and weighed weekly, and
the lumbar spine BMD was assessed monthly by DXA.
Three-months after withdrawal of corticosteroid in the
osteoporotic group, all animals were humanely killed and
their lumbar spines collected. Thus this interval includes the
healing and regeneration phase which is critical following
any orthopaedic intervention, including fixation of implants.
2.2. Bone Mineral Density (BMD). Dual-energy X-ray
absorptiometry (DXA) was conducted on the lumbar spine
(L2 to L5) of all animals using a Hologic QDR 2000 scanner
(Waltham, MA, USA. s/n 2263 software version 7.10 b
with standard array mode acquisition −1.8 uSv eﬀective X-
ray radiation dose) at the selected time points. Animals
were positioned supine on the scanner table under general
anaesthesia or immediately after death. The upper limbs were
folded and secured to the chest with masking tape, and the
lower limbs were extended and held down loosely with the
tape.
2.3. Micro CT. The fourth lumbar vertebra of each animal
was cleaned of soft tissue and the spinous processes removed
using a band saw. The vertebrae were fixed in 10% formalin
for one week, transferred to 70% ethanol, and wrapped in
polythene film to minimise dehydration during micro-CT
imaging (SkyScan 1076 in vivo scanner, SkyScan, Kontich,
Belgium). Projection images were obtained at 100 kV and
75 µA with a 1mm aluminium filter and a pixel size of
17.4 µm in all three spatial planes. A rotation step of 0.5◦
was used between each image. From this series of projection
images, two-dimensional tomographs were reconstructed,
orthogonal to the imaging plane, with NRecon software
(version 1.5.1.3, Skyscan, Kontich, Belgium). On average,
there were 2020 tomographs for each vertebra.
For histomorphometric analysis, the volume of interest
(VOI) was defined for each vertebral body. The first and last
200 tomographs from each vertebra were excluded to ensure
the endplate was not included in the analysis. The remaining
tomographs were divided into three equal zones comprising
two subendplate zones and one central zone similar to
human studies [11, 12]. Each zone was further divided into
the left and right halves (Figure 1). Each VOI was saved
as a new smaller data set to aid data processing. Using
CTAn software (version 1.8.1.2, Skyscan, Kontich, Belgium),
the following morphometric descriptors of trabecular bone
were measured from the VOI of each zone: tissue volume
(TV), bone volume (BV), percent bone volume (BV/TV),
tissue surface (TS), bone surface (BS), intersection surface
(i.S), bone surface/volume (BS/BV), bone surface density
(BS/TV), trabecular thickness (Tb.Th), trabecular separation
(Tb.Sp), and trabecular number (Tb.N) [17].
Diﬀerences between vertebral regions, body weight,
BMD, and bone morphometric parameters in control and
osteoporotic sheep were tested using one-way analysis of
variance with Tukey’s post hoc comparison of means (SAS,
SAS Institute, Cary, NC). Statistical significance was set at
P < 0.05.
3. Results
3.1. General Observations. The weight of animals during
the induction of osteoporosis did not change significantly
(Figure 2) but with the gradual withdrawal of corticosteroid,
it decreased by 11% from baseline (P < 0.01). Body weight
remained low during the first months of corticosteroid
withdrawal, and the sheep received weekly injections of
2mL Dexafort for three consecutive weeks to improve their
appetite and general wellbeing. By the end of the study, body
weight was not diﬀerent from the start.
3.2. Bone Mineral Density. BMD of the lumbar spine in the
osteoporotic sheep decreased over 30% from baseline after
five and half months (P < 0.001, Figure 3). With cessation









Figure 1: The three dimensions of a sheep vertebral body
demonstrating the regions of interest examined (two subendplate
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Figure 2: Body weight of control and osteoporotic sheep through-
out the study. The highlighted gray area shows the period of
corticosteroid withdrawal. Body weight was reduced during and one
month after withdrawal of corticosteroids (∗P < 0.05).
of corticosteroid treatment lumbar BMD did not change
significantly until the end of the study, at which time BMD
of the osteoporotic group was 23% lower than their baseline
and 25% lower than the control animals (P < 0.001).
3.3. Bone Histomorphometry. As the trabecular bone mor-
phometric parameters in both osteoporotic and control
groups did not show any diﬀerence between the left and right
side of each zone, these data were pooled for subsequent
analyses. BV/TV in the central zone of the vertebrae in both
the control and the osteoporotic sheep was lower than in
the endplate zone (P < 0.05, Figure 4(a)). Relative to the
central zone the sub-endplate zone had higher Tb.Sp, Tb.N
and BS/TV in both groups (P < 0.05, Figures 4(b), 4(c),
and 4(d)). There was no significant diﬀerence in Tb.Th
between the central and sub-endplate zones for either group
(Figure 4(e)).
Three-months after cessation of corticosteroid adminis-
tration, the osteoporotic sheep had 23% less BV/TV in both
the central and endplate zone than the controls (Figure 4(a),
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Figure 3: Percentage change in BMD in control and osteoporotic
sheep. The highlighted gray area shows the period of corticosteroid
withdrawal. BMD of osteoporotic sheep remained lower than
controls after withdrawal of corticosteroids (∗P < 0.05).
P < 0.01). Tb.Sp and Tb.N and the bone surface density
(BS/TV) in the osteoporotic sheep were not significantly
diﬀerent from the control sheep (Figures 4(b), 4(c), and
4(d)) although Tb.Th in the osteoporotic sheep was 23% and
27% less than the control sheep for the sub-endplate and
central zones, respectively, (P < 0.05, Figure 4(e)).
4. Discussion
In support of our working hypothesis, this study showed,
for the first time, persistence of the osteoporotic condition
in the lumbar spine of this animal model after cessation
of corticosteroid administration at least for three-months.
Further, the vertebral bone of sheep has been shown to be
arranged in a heterogeneous manner, with two distinct mor-
phological zones (sub-endplate and central zones), each with
very specific trabecular bone density and microstructure,
similar to humans.
It is known that rapid withdrawal of corticosteroid can
result in acute adrenal insuﬃciency, which could lead to
severe health complications [16]. In our study, the gradual
withdrawal of corticosteroids over one month was intended
to minimise potential health complications and provides an
opportunity for the animals to resume endogenous cortisol
production. However, based on our findings and those of
other research groups [18, 19], it may be necessary to further
prolong the withdrawal of steroid (perhaps to seven weeks)
to minimise such complications.
On average, BMD of the spine of osteoporotic sheep, 3
months after the cessation of corticosteroid administration,
was 25% lower than the control group, confirming that they
maintained their osteoporotic condition. The three-month
endpoint was selected to include an important phase of
the bone healing process. This confirms the findings from
a similar study that demonstrated BMD, microarchitecture,
and mechanical competence in the tibia and femur (but
not the spine) remained osteopenic six months after the





































































































Figure 4: Comparison of histomorphometric indices of trabecular bone from diﬀerent regions of lumbar vertebrae in control and
osteoporotic sheep (∗P < 0.05, ∗∗P < 0.01).
cessation of glucocorticoid treatment [18]. Further support-
ing our data, it also showed that BMD in the distal radius
of osteoporotic sheep remained significantly lower almost
seven months after the end of steroid administration [19].
However, these findings contrasted with more recent work
that showed BMD of the spine in an osteopenic sheep model
improved to the control level group three-months after the
cessation of corticosteroid [20]. This contradictory finding
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was likely due to the presence of normal sex hormone levels
in this model compared to our ovariectomised sheep model.
These findings demonstrate the significance of synergistic
eﬀects of ovariectomy and corticosteroid treatment on bone
in the animal model described herein.
An appreciation of bone architecture is essential for the
assessment of fracture risk and interpretation of clinical
data [12, 21]. It has been documented that human vertebral
bodies are heterogeneous, with two distinct morphological
zones (subendplate and central zones), each with very
specific trabecular bone density and microstructure [12].
The clinical significance of this heterogeneity has been
discussed [12], specifically in relation to the pathogenesis of
fractures [22, 23]. Micro-CT analysis shows that the central
zone of sheep vertebrae has lower bone volume but thicker
trabeculae that are spaced further apart, similar to humans
[12, 22], although with no lateral variability [24]. The higher
bone volume in the sub-endplate region is due mainly to
an increase in the number of trabeculae with an associated
increased trabecular surface density. The osteoporotic sheep
had lower bone volume, mainly as a result of thinner
trabeculae. Thus, it is concluded that the reduction of BMD
in vertebrae is due mainly to trabecular thinning that leads
to biomechanically weaker vertebrae [8]. Such information
would have significant clinical application for testing or
validation of surgical implants in this animal model. It
should be noted, however, that structural components other
than trabecular bone, including the endplate, the cortical
shell, the posterior elements, osteophytes, and intervertebral
discs will also contribute to vertebral strength [21, 25–27].
Thus further characterisation of the structural components
of the spine in this animal model is required to extend its
applicability for preclinical studies.
In conclusion, the sheep model reported here, which has
been validated previously [8–10] is one of severe bone loss
that is achieved in a relatively short period, and impor-
tantly, in a relatively long-lived, large animal with vertebral
trabecular bone microarchitecture similar to humans. The
data also demonstrated that bone mass and BMD of this
model remained at the osteoporotic level at the end of
three-months, indicating that the model is suitable for
investigating the early eﬀects of surgical or pharmacological
treatments on bone. We acknowledge this osteoporotic
sheep model, like all other animal models does not fully
mimic either post-menopausal or corticosteroid-induced
osteopenia in humans, and the eﬀects of glucocorticoids
as well as estrogen deficiency and calcium deficiency are
not easily separable. Nonetheless, the aetiology of human
postmenopausal osteoporosis is also complex and is not due
simply to the loss of oestrogen but rather is influenced by
myriad factors including genetic predisposition and body
weight, as well as environmental factors, such as vitamin
D and calcium insuﬃciency, level of exercise or mobility,
and various forms of medication, including anticoagulants
and glucocorticoids. We believe this animal model is suitable
for conducting preclinical trials of novel pharmacologic or
surgical interventions for osteoporosis of the lumbar spine
as well as other clinically relevant sites. However, a longer
follow-up study (six months to one year) after discontinu-
ation of corticosteroids, including additional molecular and
histomorphometric investigations, would further confirm
the applicability of this model to understand the long-term
eﬀects of potential interventions for treating osteoporotic
bone.
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